Haemonetics Corporation HAE
-
New Morningstar Analyst Report - ViroPharma, Inc.
… last few years.Heightened competition in HAE 's acute arena has the potential to relegate ..... approved product for the prevention of HAE attacks. Given the high level of mortality and lack of treatment options for HAE , Cinryze should command significant pricing …
-
Pall Sells Blood Business to Haemonetics for $550 million
Pall PLL announced that it has sold its blood collection, filtration, and processing products to Haemonetics HAE for $550 million, which is roughly 2.4 times the units 2012 sales. We think this divestiture makes sense for Pall in that …
-
Haemonetics ( HAE ): Q1 EPS of $0.80 misses by $0.03. Revenue of $186.7M (+9.8% Y/Y) beats by $3M. (PR)
Haemonetics ( HAE ): Q1 EPS of $0.80 misses by $0.03 . Revenue of $186.7M (+9.8% Y/Y) beats by $3M . ( PR ) Post your comment!
-
Haemonetics ( HAE ): FQ3 EPS of $0.86 beats by $0.80. Revenue of $191.2M (+8.1% Y/Y) beats by $5M. (PR)
Haemonetics ( HAE ): FQ3 EPS of $0.86 beats by $0.80 . Revenue of $191.2M (+8.1% Y/Y) beats by $5M . ( PR ) Post your comment!
-
Haemonetics Corporation HAE Q3 2012 Earnings Call Transcript
Good day, ladies and gentlemen and welcome to the Third Quarter 2012 Haemonetics Corporation Earnings Conference Call. My name is, (Camara), and I'll be your coordinator for today. At this time all participants are …
-
Maintaining Viropharma's Credit Rating
… product is Cinryze--the first treatment approved in the U.S. for the prevention of hereditary angioedema, or HAE , attacks. Given HAE 's orphan status and lack of alternative preventative options, ViroPharma benefits from both exclusivity and …
-
ViroPharma Is Poised For Gain
… recurrent C. difficile infection (CDI). The company’s commercial products address diseases including hereditary angioedema ( HAE ), seizures and C. difficile-associated diarrhea (CDAD). click to enlarge image Long term, health care reform legislation …
-
Medical device manufacturer Haemonetics ([[ HAE ]] -3.5%) gets hit after its FQ2 misses EPS estimates, despite beating on revenue. Profits rose 8% Y/Y, but net income declined 35% due to quality issues ...
Medical device manufacturer Haemonetics ( HAE -3.5% ) gets hit after its FQ2 misses EPS estimates, despite beating on revenue. Profits rose 8% Y/Y, but net income declined 35% due to quality issues with it HS Core Bowl the recall of its OrthoPAT device. Post your comment!
-
Key Companies And Products In The Market To Treat The Orphan Disease Hereditary Angioedema
… development for the treatment of Hereditary Angioedema ( HAE ), a rapidly growing market. The HAE market is in an early and dynamic period of growth ..... investment outlook for the companies involved in HAE in subsequent reports because there are other aspects …
-
Dropping Coverage of Haemonetics Corporation
We are no longer providing equity research on Haemonetics Corporation HAE . We provide broad coverage of more than 1,700 companies across more than 140 industries, and adjust our coverage as necessary based on client demand and investor interest.